Regorafenib in adult patients with recurrent glioblastoma: a single-arm meta-analysis.
Marcos Henrique da Silva Mezzari, Natan Lucca Lima, Bárbara Ghizoni Maggi et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and single-arm meta-analysis pooled outcomes from ten studies of regorafenib in 724 adults with recurrent glioblastoma. Median overall survival was 7.2 months and median progression-free survival was 2.6 months; 12-month overall survival was 22.5% and 6-month progression-free survival was 14.9%. Disease control was reported in 36.1%, while grade 3–4 adverse events occurred in 31.4%. Meta-regression associated MGMT methylation with better survival and disease-control outcomes, and male sex with better overall survival and stable disease.
Key findings
- Across ten studies and 724 patients, median overall survival was 7.2 months and median progression-free survival was 2.6 months.
- The 12-month overall survival rate was 22.5%, and the 6-month progression-free survival rate was 14.9%.
- Disease control rate was 36.1%; grade 3-4 adverse events occurred in 31.4%.
- Meta-regression associated MGMT methylation with improved outcomes; male sex was associated with better overall survival and stable disease.
Why it matters
The pooled estimates provide a summary of reported survival, disease control, and higher-grade toxicity with regorafenib in recurrent glioblastoma, where treatment options are limited. The biomarker and sex associations may help frame questions for further study, but they are meta-regression findings and do not establish which patients will benefit.
What to keep in mind
The analysis was single-arm, pooling studies without a comparator; its findings cannot establish regorafenib's benefit relative to other treatments.